In-Depth Notes on Pathway-Targeted Therapies

Pathway-Targeted Therapies

  • Overview: Targeted cancer therapies are designed to block the growth and spread of cancer by interfering with specific molecules (oncogenic proteins).
  • Difference from Standard Therapies:
    • Targeting: Targeted therapies act on specific molecular targets associated with cancer. Standard chemotherapies act on all rapidly dividing normal and cancer cells.
    • Mechanism: Targeted therapies block tumor cell proliferation (cytostatic), whereas standard chemotherapies kill tumor cells (cytotoxic).

Types of Targeted Cancer Therapies

  • Monoclonal Antibodies:
    • Large biological drugs used for targets outside cells or on cell surfaces.
    • Functions include blocking receptor functions, recruiting immune cells, and delivering toxins; administered via IV infusion.
  • Small-Molecule Compounds:
    • Developed for targets inside cells; administered orally and often metabolized by CYP3A4.

Sections of Pathway-Targeted Therapies

  1. Growth factors and receptors in cancer cells
  2. Intracellular kinases in cancer cells
  3. Tumor-host interactions reflected in aberrant tumor angiogenesis
  4. Restoring immune recognition of cancer cells
  5. Other drugs and targets controlling cancer cell behavior

Growth Factors and Receptors

  • EGFR Inhibitors:
    • Function: Inhibit EGFR, crucial for epithelial cell growth.
    • Drugs: Cetuximab, Panitumumab (monoclonal antibodies), Erlotinib, Gefitinib, Afatinib (small-molecule inhibitors).
    • Mechanism: Block receptor function or inhibit tyrosine kinase activity.
    • Adverse Effects: Diarrhea, fatigue, skin rash, risk of lung disease.
Detailed Overview of EGFR Inhibitors

  1. Small-Molecule EGFR Kinase Inhibitors:

    • First Generation: Erlotinib and Gefitinib.
      • Uses: Advanced metastatic NSCLC.
    • Second Generation: Afatinib.
      • Uses: First-line for metastatic NSCLC with EGFR mutations.
    • Third Generation: Osimertinib.
      • Uses: Specifically targets T790M mutant EGFR in resistant NSCLC.

  2. Monoclonal Antibody EGFR Inhibitors:

    • Examples: Cetuximab, Panitumumab, Necitumumab.
    • Uses: Colorectal cancer, head and neck cancer, NSCLC.
    • Mechanism: Prevents dimerization and signaling.
    • Adverse Effects: Skin rash, interstitial lung disease.

HER2/Neu Inhibitors

  • Overview: HER2 is a receptor involved in aggressive breast cancer.
  • Drugs: Lapatinib, Neratinib, Tucatinib (small-molecule), Trastuzumab, Pertuzumab, Margetuximab (monoclonal antibodies).
  • Function: Inhibit HER2 activation and signaling, activating immune response against cancer cells.
  • Adverse Effects: Diarrhea, rash, hepatotoxicity, cardiotoxicity.

Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors

  • Function: Involved in tumor growth and angiogenesis.
  • Drug: Avapritinib, targeting PDGFR-alpha.
    • Uses: GISTs with PDGFR-alpha mutations.
  • Adverse Effects: Edema, nausea, dizziness.

Intracellular Protein Kinase Inhibitors

  • Types:
    • B-RAF Kinase Inhibitors (e.g., Vemurafenib, Dabrafenib)
    • MEK Inhibitors (e.g., Trametinib)
    • JAK Inhibitors (e.g., Ruxolitinib).
  • General Mechanism: Block specific kinases, disrupting signal transduction involved in cancer cell growth.
  • Adverse Effects: Skin issues, gastro intestinal symptoms, QT prolongation.

Conclusion

  • Pathway-targeted therapies offer a tailored approach to cancer treatment by specifically targeting molecular abnormalities in tumor cells, which can lead to better efficacy and reduced side effects compared to traditional chemotherapy methods.